Schering contrast agent debuts in Sweden:
This article was originally published in Clinica
Executive Summary
Schering (Berlin, Germany) has gained approval for its liver specific-contrast agent, Resovist, in Sweden. Schering used the EU's mutual recognition procedure to gain the approval, which marks the worldwide marketing debut of the product. Resovist was developed in collaboration with Japan's Meito Sangyo. It will be launched in Sweden in mid-2001. The agent is injected as an intravenous bolus and can detect and characterise small liver focal lesions, enabling early detection of hepatic carcinoma or metastases. Imaging is immediate, cutting down examination time. Schering claims a 60 % share of world MRI contrast agent sales.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.